RET and medullary thyroid gland carcinoma: Selpercatinib received an accelerated approval from the FDA in May 2020 for treatment of patients with metastatic RET-fusion positive NSCLC, advanced/metastatic RET-mutant medullary thyroid cancer, and advanced/metastatic RET-fusion-positive thyroid cancer.10